2024
Neurofilament light chains: A biomarker for vincristine-related neuropathy.
McNally G, Xu M, Voorhees T, Baiocchi R, Bond D, Epperla N, Maddocks K, Sawhala Y, Ramaswamy B, Lustberg M. Neurofilament light chains: A biomarker for vincristine-related neuropathy. Journal Of Clinical Oncology 2024, 42: 12114-12114. DOI: 10.1200/jco.2024.42.16_suppl.12114.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyPatient-reported outcomesNF-L levelsPeripheral neuropathyTime point 3Cancer Institute Common Terminology Criteria for Adverse EventsNational Cancer Institute Common Terminology Criteria for Adverse EventsCommon Terminology Criteria for Adverse EventsAggressive non-Hodgkin's lymphomaSymptoms of chemotherapy-induced peripheral neuropathyDose-adjusted EPOCHNon-Hodgkin's lymphomaNF-LVincristine-induced neurotoxicityTime pointsLight chainClinician-reported outcome measuresNeurofilament light chainEuropean Organization for Research and TreatmentCycle fourLymphoma treatmentLong-term qualityBlood-based biomarkersChemotherapy typeAdverse eventsA retrospective cohort study describing chemotherapy-induced peripheral neuropathy in Non-Hodgkin lymphoma patients treated with EPOCH ± R: does HIV status matter?
McNally G, Aossey C, Wiczer T, Sinnott L, Lustberg M, Baiocchi R, Lustberg M. A retrospective cohort study describing chemotherapy-induced peripheral neuropathy in Non-Hodgkin lymphoma patients treated with EPOCH ± R: does HIV status matter? Leukemia & Lymphoma 2024, 65: 1110-1116. PMID: 38648546, DOI: 10.1080/10428194.2024.2340051.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyIncidence of chemotherapy-induced peripheral neuropathyHIV statusPeripheral neuropathyHIV-associated non-Hodgkin's lymphomaCohort studyDose-adjusted EPOCHNon-Hodgkin's lymphomaLong-term patient outcomesRetrospective cohort studyNon-HodgkinComprehensive cancer centerCancer CenterHIVPatientsNeuropathyPatient outcomesPropensity scoreLymphomaAdverse effectsIncidenceStatusRegimenVincristine
2023
Patient perceptions of altering chemotherapy treatment due to peripheral neuropathy
Hertz D, Tofthagen C, Rossi E, Bernasconi D, Lim J, Carlson M, Sheffield K, Nekhlyudov L, Grech L, Von Ah D, Mayo S, Ruddy K, Chan A, Alberti P, Lustberg M, Tanay M. Patient perceptions of altering chemotherapy treatment due to peripheral neuropathy. Supportive Care In Cancer 2023, 32: 48. PMID: 38129602, DOI: 10.1007/s00520-023-08209-0.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyNeurotoxic chemotherapy treatmentChemotherapy treatmentSymptom resolutionPeripheral neuropathySevere chemotherapy-induced peripheral neuropathyCommon reason participantsMethodsA cross-sectional online surveyBetter patient educationCross-sectional online surveyNeurotoxic chemotherapyCIPN symptomsMedian ageMost patientsTreating clinicianLong-term benefitsPatients' perceptionsPatient educationPractice guidelinesTreatment goalsClinicians' understandingTreatment efficacyConclusionsThis surveyPatientsSymptomsEvolution of predictive risk factor analysis for chemotherapy-related toxicity
Hertz D, Lustberg M, Sonis S. Evolution of predictive risk factor analysis for chemotherapy-related toxicity. Supportive Care In Cancer 2023, 31: 601. PMID: 37773300, DOI: 10.1007/s00520-023-08074-x.Peer-Reviewed Original ResearchConceptsTreatment-related toxicityBiomarker discovery approachClinical practiceTaxane-induced peripheral neuropathyChemotherapy-related toxicitySame treatment regimenMaximum treatment benefitRisk factor analysisPrecision oncology treatmentsToxicity riskPeripheral neuropathyTreatment regimenSimilar patientsToxicity predictorsTreatment benefitPharmacogenetic predictorsOncology treatmentSide effectsTherapeutic outcomesCancer treatmentMinimal toxicityIntegrated biomarkersGermline genomicsBiomarker sciencePatientsA phase Ib adaptive study of dasatinib for the prevention of oxaliplatin-induced neuropathy in patients with gastrointestinal (GI) cancers receiving FOLFOX chemotherapy with or without bevacizumab.
Noonan A, Farid S, Schnell P, Trunzo D, Malalur P, Jin N, Manne A, Abushahin L, Rahman S, Hays J, Elkhatib R, Mittra A, Roychowdhury S, Lustberg M, Sparreboom A, Hu S. A phase Ib adaptive study of dasatinib for the prevention of oxaliplatin-induced neuropathy in patients with gastrointestinal (GI) cancers receiving FOLFOX chemotherapy with or without bevacizumab. Journal Of Clinical Oncology 2023, 41: e15613-e15613. DOI: 10.1200/jco.2023.41.16_suppl.e15613.Peer-Reviewed Original ResearchOrganic cation transporter 2Efficacy biomarkersRandomized phase II studyRat dorsal root gangliaAmount of oxaliplatinPhase 2 doseOxaliplatin-induced neuropathyPhase II studyPhase I trialDose-finding studyDorsal root gangliaLevels of biomarkersMajority of ptsFOLFOX chemotherapyFOLFOX regimenOX administrationII studyI trialPeripheral neuropathyGastrointestinal cancerGI cancersPreclinical dataRoot gangliaSerum biomarkersCohort 2Identifying factors that influence the decision to reduce, delay, or discontinue treatment due to chemotherapy-induced peripheral neuropathy: A community-centered approach.
Radwan R, Hertz D, Hickey E, Vachhani H, Lustberg M, Bridges J, Sabo R, Sheppard V, Salgado T. Identifying factors that influence the decision to reduce, delay, or discontinue treatment due to chemotherapy-induced peripheral neuropathy: A community-centered approach. Journal Of Clinical Oncology 2023, 41: e13123-e13123. DOI: 10.1200/jco.2023.41.16_suppl.e13123.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyMetastatic breast cancerPeripheral neuropathyTreatment alterationsTreatment effectivenessMBC patientsCIPN symptomsMedical oncologistsDiscontinue treatmentClinical guidelinesOncology cliniciansCommunity-centered approachEffective therapyBreast cancerChemotherapy agentsTreatment decisionsPatient prioritiesPatient's perspectiveDose reductionAlternative treatmentOptimize outcomesPatientsSide effectsTreatment planHealthcare providersIdentification of a SNP cluster associated with taxane-induced peripheral neuropathy risk in patients being treated for breast cancer using GWAS data derived from a large cooperative group trial
Lustberg M, Wu X, Fernández-Martínez J, de Andrés-Galiana E, Philips S, Leibowitz J, Schneider B, Sonis S. Identification of a SNP cluster associated with taxane-induced peripheral neuropathy risk in patients being treated for breast cancer using GWAS data derived from a large cooperative group trial. Supportive Care In Cancer 2023, 31: 139. PMID: 36707490, DOI: 10.1007/s00520-023-07595-9.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyLarge cooperative group trialsCooperative group trialsIndependent patient cohortsCancer chemotherapy regimenCIPN riskCommon toxicitiesTaxane exposureChemotherapy regimenNeuropathy riskPeripheral neuropathyPatient cohortClinical trialsBreast cancerGroup trialsEffective interventionsPatientsRisk determinationInconsistent resultsECoGTrialsPresent studyRiskDiscriminatory powerHigh predictive accuracy
2021
Financial Burden of Drugs Prescribed for Cancer-Associated Symptoms
Gupta A, Nshuti L, Grewal US, Sedhom R, Check DK, Parsons HM, Blaes AH, Virnig BA, Lustberg MB, Subbiah IM, Nipp RD, Dy SM, Dusetzina SB. Financial Burden of Drugs Prescribed for Cancer-Associated Symptoms. JCO Oncology Practice 2021, 18: 140-147. PMID: 34558297, PMCID: PMC9213200, DOI: 10.1200/op.21.00466.Peer-Reviewed Original ResearchConceptsCancer-associated symptomsChemotherapy-induced peripheral neuropathyCancer-associated fatigueSymptom control drugsPatient-clinician discussionsExocrine pancreatic insufficiencyCost of drugsBrand-name formulationProphylaxis regimenPeripheral neuropathyDrug prescribedPancreatic insufficiencyNew agentsControl drugSame drugFinancial toxicitySymptomsDrugsFinancial burdenRelevant guidelinesAnticancer drugsSO-17 The global POLAR program: Top-line results of placebo-controlled studies of calmangafodipir on top of modified FOLFOX6 to prevent chemotherapy-induced peripheral neuropathy
Qvortrup C, Muro K, Lustberg M, Persson A, Näsström J, Carlsson S, Nagahama F, Pfeiffer P. SO-17 The global POLAR program: Top-line results of placebo-controlled studies of calmangafodipir on top of modified FOLFOX6 to prevent chemotherapy-induced peripheral neuropathy. Annals Of Oncology 2021, 32: s209-s210. DOI: 10.1016/j.annonc.2021.05.041.Peer-Reviewed Original ResearchPatient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN)
Hertz DL, Childs DS, Park SB, Faithfull S, Ke Y, Ali NT, McGlown SM, Chan A, Grech LB, Loprinzi CL, Ruddy KJ, Lustberg M. Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN). Cancer Treatment Reviews 2021, 99: 102241. PMID: 34174668, DOI: 10.1016/j.ctrv.2021.102241.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyNeurotoxic chemotherapy treatmentTreatment alterationsCIPN severityPeripheral neuropathyPatient factorsChemotherapy treatmentRelative dose intensityClinical Oncology guidelinesNeurotoxic chemotherapyDose intensityProspective trialOncology guidelinesRetrospective analysisAdult cancersIndividual patientsInconsistent recommendationsPatientsTreatment efficacyClinical decisionSeverityNeuropathyAmerican SocietyTreatmentCliniciansSupportive Care: Low Cost, High Value.
Popescu RA, Roila F, Arends J, Metro G, Lustberg M. Supportive Care: Low Cost, High Value. American Society Of Clinical Oncology Educational Book 2021, 41: 1-11. PMID: 33830830, DOI: 10.1200/edbk_320041.Peer-Reviewed Original ResearchConceptsQuality of lifePhysical exerciseChemotherapy-induced peripheral neuropathyLarge phase III trialsElectronic patient-reported outcome measuresPatient-reported outcome measuresPersonalization of chemotherapySupportive care unitPhase III trialsSupportive care interventionsCancer-related fatigueMind-body interventionsNonpharmacologic strategiesScrambler therapyGastrointestinal dysmotilityIII trialsOverall survivalSupportive careTreatable causeMuscle trainingPeripheral neuropathyCare unitClinic appointmentsMetabolic derangementsRegular screeningEmerging Pharmacological and Non-Pharmacological Therapeutics for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy
Li Y, Lustberg MB, Hu S. Emerging Pharmacological and Non-Pharmacological Therapeutics for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy. Cancers 2021, 13: 766. PMID: 33673136, PMCID: PMC7918689, DOI: 10.3390/cancers13040766.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyPeripheral neuropathyPathogenesis of CIPNTreatment of CIPNFirst-line chemotherapeutic agentNon-pharmacological therapeuticsCommon adverse eventsNon-pharmacological strategiesQuality of lifeAdverse eventsClinical outcomesCancer survivorsEffective intervention strategiesClinical trialsSide effectsChemotherapeutic agentsEffective interventionsVinca alkaloidsNew targetsIntervention strategiesNeuropathyPrior failureClinical researchersPlatinum compoundsTherapeutics
2020
A phase Ib adaptive study of dasatinib for the prevention of oxaliplatin-induced neuropathy in patients with metastatic colorectal cancer receiving FOLFOX chemotherapy and bevacizumab.
Noonan A, Lustberg M, Schnell P, Hays J, Jin N, Abushahin L, Malalur P, Roychowdhury S, Elkhatib R, Chen H, Al Mutar S, Sparreboom A, Hu S. A phase Ib adaptive study of dasatinib for the prevention of oxaliplatin-induced neuropathy in patients with metastatic colorectal cancer receiving FOLFOX chemotherapy and bevacizumab. Journal Of Clinical Oncology 2020, 38: tps12125-tps12125. DOI: 10.1200/jco.2020.38.15_suppl.tps12125.Peer-Reviewed Original ResearchOxaliplatin-induced peripheral neuropathyOxaliplatin-induced neuropathyOrganic cation transporter 2Peripheral neuropathyColorectal cancerChronic oxaliplatin-induced peripheral neuropathyStage IV colorectal cancerRat dorsal root gangliaOxaliplatin-induced neurotoxicityPharmacokinetics of oxaliplatinPhase 2 doseMetastatic colorectal cancerPhase 1b trialDose-finding studyDorsal root gangliaAddition of dasatinibQuality of lifeSmall molecule kinase inhibitorsFOLFOX chemotherapyOral dasatinibBevacizumab therapyRoot gangliaSerum biomarkersIntermittent doseRat modelA phase Ib study of the safety and pharmacology of nilotinib to prevent paclitaxel-induced peripheral neuropathy in patients with breast cancer.
Adams E, Lustberg M, Jin Y, Li Y, Sparreboom A, Hu S. A phase Ib study of the safety and pharmacology of nilotinib to prevent paclitaxel-induced peripheral neuropathy in patients with breast cancer. Journal Of Clinical Oncology 2020, 38: tps12128-tps12128. DOI: 10.1200/jco.2020.38.15_suppl.tps12128.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyPaclitaxel infusionFree survivalPeripheral neuropathyBreast cancerPaclitaxel-induced peripheral neuropathyBreast cancer stage IEarly-stage breast cancerGrade 2 neuropathyPhase Ib studyPhase II doseDisease-free survivalCancer stage IStage breast cancerBreast cancer therapyTyrosine kinase inhibitorsQuality of lifeOrganic anion transportingOATP1B1 inhibitionOral nilotinibWeekly paclitaxelPaclitaxel dosePaclitaxel therapyOverall survivalWeekly doses
2019
The Global POLAR program: Calmangafodipir used on top of modified FOLFOX6 (5-FU/FA and oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN).
Pfeiffer P, Qvortrup C, Muro K, Lustberg M, Nagahama F, Sonehara Y, Bengtson M, Nittve M, Sonesson C, Carlsson C. The Global POLAR program: Calmangafodipir used on top of modified FOLFOX6 (5-FU/FA and oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN). Journal Of Clinical Oncology 2019, 37: tps722-tps722. DOI: 10.1200/jco.2019.37.4_suppl.tps722.Peer-Reviewed Original ResearchMetastatic colorectal cancerProportion of patientsFree survivalSafety endpointCumulative doseHigh-risk stage IIAdditional safety endpointsProgressive-free survivalCommon adverse eventsOxaliplatin-induced neuropathyDisease-free survivalPatient reported symptomsTreatment of patientsManganese superoxide dismutase activitySuperoxide dismutase mimeticFOLFOX6 chemotherapyMFOLFOX6 chemotherapyOXA treatmentPrimary endpointAdverse eventsFirst doseOverall survivalMS patientsPeripheral neuropathyTreatment breaks
2017
Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients
Monfort S, Pan X, Patrick R, Ramaswamy B, Wesolowski R, Naughton M, Loprinzi C, Chaudhari A, Lustberg M. Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients. Breast Cancer Research And Treatment 2017, 164: 69-77. PMID: 28374323, PMCID: PMC5510549, DOI: 10.1007/s10549-017-4230-8.Peer-Reviewed Original ResearchConceptsBreast cancer patientsPatient-reported outcomesTaxane-based chemotherapyCancer patientsChemotherapy cyclesEarly-stage breast cancer patientsPatient-reported symptom severityDevelopment of CIPNSubsequent chemotherapy cyclesFirst chemotherapy cyclePatient-reported symptomsDose-limiting toxicityOutpatient oncology clinicsSelf-reported symptomsTaxane infusionTaxane therapyTaxane treatmentCIPN symptomsDose intensityPeripheral neuropathyOncology clinicPatient functionPhysical functionFunctional deficitsGait testingEffect of chemotherapy-induced peripheral neuropathy on postural control in cancer survivors.
Herman H, Monfort S, Pan X, Chaudhari A, Lustberg M. Effect of chemotherapy-induced peripheral neuropathy on postural control in cancer survivors. Journal Of Clinical Oncology 2017, 35: 128-128. DOI: 10.1200/jco.2017.35.5_suppl.128.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathySensory symptomsCancer patientsCIPN symptomsPeripheral neuropathyPostural controlCommon dose-limiting toxicityEORTC QLQ-CIPN20Patients' sensory symptomsDose-limiting toxicityPoor controlPost-treatment sequelaeRisk of fallsCourse of treatmentQuality of lifeQLQ-CIPN20Oxaliplatin chemotherapyCurative treatmentCancer survivorsCenter of pressureClose monitoringPatientsPoor balancePostural stabilityNeuropathy
2014
Management options for established chemotherapy-induced peripheral neuropathy
Pachman D, Watson J, Lustberg M, Wagner-Johnston N, Chan A, Broadfield L, Cheung Y, Steer C, Storey D, Chandwani K, Paice J, Jean-Pierre P, Oh J, Kamath J, Fallon M, Strik H, Koeppen S, Loprinzi C. Management options for established chemotherapy-induced peripheral neuropathy. Supportive Care In Cancer 2014, 22: 2281-2295. PMID: 24879391, DOI: 10.1007/s00520-014-2289-x.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyPeripheral neuropathyTreatment of CIPNPeripheral neuropathy syndromesCancer treatment outcomesQuality of lifeClinical practice experienceCIPN treatmentNeuropathy syndromesTreatment optionsTreatment outcomesTherapeutic interventionsChemotherapeutic agentsPsychosocial functioningAvailable evidenceLimited evidenceNeuropathyPatientsTreatmentCliniciansAvailable literaturePractice experienceManagement optionsEvidenceOptionsPrevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
Hershman D, Lacchetti C, Dworkin R, Lavoie Smith E, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg M, Paice J, Schneider B, Smith M, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi C. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. Journal Of Clinical Oncology 2014, 32: 1941-1967. PMID: 24733808, DOI: 10.1200/jco.2013.54.0914.Peer-Reviewed Original ResearchMeSH KeywordsAdultAminesAmitriptylineAnalgesicsAnticonvulsantsAntidepressive Agents, TricyclicAntineoplastic AgentsBaclofenComorbidityCyclohexanecarboxylic AcidsDrug Therapy, CombinationDuloxetine HydrochlorideEvidence-Based MedicineGabapentinGamma-Aminobutyric AcidGelsHumansIncidenceKetamineNeoplasmsNeuralgiaPeripheral Nervous System DiseasesQuality of LifeRandomized Controlled Trials as TopicSeverity of Illness IndexSurvivorsThiophenesTreatment OutcomeUnited StatesConceptsChemotherapy-induced peripheral neuropathyPeripheral neuropathyPrimary outcomePrevention of CIPNTreatment of CIPNClinical Oncology Clinical Practice GuidelineOncology Clinical Practice GuidelineNeuropathic pain conditionsSeverity of neuropathyClinical practice guidelinesPatient-reported outcomesAdult cancer survivorsQuality of lifeSystematic literature searchEvidence-based guidanceDifferent time pointsPain conditionsCancer survivorsTreatment optionsTricyclic antidepressantsPractice guidelinesAdult cancersNeurophysiologic changesEligibility criteriaTreatment approaches